The Biostatistics Core for this program project is staffed with members of the Biostatistics and Informatics Shared Resource of the Masonic Cancer Center. The working principles of this Core reflect those delineated in a recent report from the working group convened by the Royal Statistical Society to study statistical and scientific issues related to 'First in man Studies'(March 2007). Their views are exemplified by the quote "Statistician's input concerns matters of ethics, science, and public health, reporting standards, practicality and common sense, not just the purely methodological." In addition, the team that prepared this application will also support the critical need for sound, secure and efficient data systems and appropriate quality assurance and quality control procedures. To that end, the primary objective of the Biostatistics Core is to contribute to the science and operation of the program project by participating fully in its activities as it has for the preparation of this application. This includes assistance and direction in experimental design, quality control, data collection and management, and statistical data analysis through consultation and collaboration.
The Specific Aims of the Core are as follows: SA 1: Assist in experimental designs and provide data analysis plans. SA 2: Develop new biostatistical methods when necessary and appropriate SA 3: Implement Quality Assurance (QA) plans for all data collection activities SA 4: Support existing and develop new (when necessary) database applications for data collection and integration.
Core B provides vital biostatistical services which will ensure safe planning, conduct and analysis of animal studies and clinical trials. In addition, the team will support sound, secure and efficient data systems and appropriate quality assurance and quality control procedures.These biostatistical support and data system management services are crucial to the overall goal of the program project to improve treatment of lethal hematologic malignancies.
|Foley, Bree; Felices, Martin; Cichocki, Frank et al. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 258:45-63|
|Mitchell, Richard; Wagner, John E; Hirsch, Betsy et al. (2014) Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. Br J Haematol 164:384-95|
|Miller, Jeffrey S; Rooney, Cliona M; Curtsinger, Julie et al. (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20:1252-7|
|Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97|
|Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26|
|Kharbanda, Sandhya; Smith, Angela R; Hutchinson, Stephanie K et al. (2014) Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant 20:581-6|
|Sawitzki, Birgit; Brunstein, Claudio; Meisel, Christian et al. (2014) Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant 20:173-82|
|Ustun, Celalettin; Bachanova, Veronika; Shanley, Ryan et al. (2014) Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. Leuk Lymphoma 55:358-64|
|Kaliyaperumal, Saravanan; Watkins, Benjamin; Sharma, Prachi et al. (2014) CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. Blood 123:1967-9|
|Rogosheske, J R; Fargen, A D; DeFor, T E et al. (2014) Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival. Bone Marrow Transplant 49:122-5|
Showing the most recent 10 out of 160 publications